Introduction
============

Several imaging techniques may reveal vascular calcium deposits. Since these deposits are not always the prime reason for the investigation, the presence of calcified blood vessel walls or heart valves is often not recognized as a clinically important sign of vascular risk. Although calcifications may occur in small amounts in the earlier stages of atherosclerosis, they are usually seen in more advanced lesions.[@b1-vhrm-5-185] Indeed, various studies have observed an increased cardiovascular risk in patients with calcification.[@b2-vhrm-5-185]--[@b8-vhrm-5-185] However, the latter is not a uniform finding.[@b9-vhrm-5-185] This discrepancy may be due to differences in methodology, patient selection and baseline risk. Recent meta-analyses of the relationship between calcification and vascular risk have focused exclusively on coronary calcium scores.[@b10-vhrm-5-185] As patients with coronary insufficiency are more likely to be subjected to diagnostic imaging than others, part of the relationship between coronary calcification and outcome may be confounded by indication. To overcome this problem, we performed the present meta-analysis in which we assessed the impact of calcium deposits in any artery or heart valve, with different imaging techniques, on fatal and nonfatal cardiovascular events as well as total mortality in populations with different baseline risks.

Methods
=======

To identify studies on vascular calcification (mineralization detected in any part of the blood vessel wall or heart valves) and cardiovascular risk, a PubMed, Embase, and Cochrane library search was performed using the following search terms: "plain radiography *or* chest X-ray *or* abdominal X-ray *or* mammography *or* panoramic radiography *or* ultrasound (US) *or* computer tomography (CT) *or* magnetic resonance imaging (MRI)" *and* (cardiovascular risk *or* calcification). Two investigators (RJMW Rennenberg and AA Kroon) screened all abstracts and, after applying the criteria for eligibility, decided on whether or not the full papers should be retrieved. All authors reviewed qualifying papers.

Study eligibility
-----------------

Only prospective cohort studies were eligible. Paediatric studies were excluded. Articles published between 1970 and June 2008, with prospective data on human vascular calcification and well-documented end-points were selected. Case reports were excluded. Data on events in both groups, with and without calcification, had to be reported separately. To be selected for the analysis absolute numbers, ie, a two-by-two table, should be extractable from the text. References found in the selected papers that fulfilled these criteria were also selected. Only papers published in English, German, Dutch, and French were considered. When data were published in consecutive articles by the same authors only the article with the most comprehensive dataset was considered.[@b8-vhrm-5-185],[@b11-vhrm-5-185]--[@b13-vhrm-5-185]

Definition of end-points
------------------------

End-points were defined as all cause mortality, cardiovascular mortality (death from any cardiovascular cause), coronary event (myocardial infarction, coronary mortality, percutaneous coronary angioplasty or coronary artery bypass operation), stroke (ischemic and hemorrhagic) and any cardiovascular event (cardiovascular mortality, coronary event, stroke, peripheral revascularisation procedures or amputation, carotid endarterectomy).

Statistical analysis
--------------------

Studies reporting data suitable to make two by two tables of calcification in relation to events were used to compute odds ratio's using a random effects meta-analysis. Because we expected significant heterogeneity, a meta-regression analysis with a random effect model was performed, as suggested by Egger and colleagues,[@b14-vhrm-5-185] taking into account the following variables: duration of follow up, type of imaging technique (plain radiograph, CT, or US) and baseline risk of the population, estimated as low (asymptomatic without known cardiovascular risk factors), intermediate (asymptomatic with one or more cardiovascular risk factors or diabetes but no renal insufficiency) and high (symptomatic or renal insufficiency). Publication bias was assessed with a funnel plot of the risk for any cardiovascular event. Statistical calculations were done using the STATA statistical program version 8.2 (StataCorp, College Station, TX), with the latest updates.

Results
=======

We originally retrieved over 2,500 articles. Screening of abstracts and exclusion of case-reports resulted in 91 remaining original studies on the association between human vascular or valvular calcifications and cardiovascular risk. After applying the eligibility criteria 61 studies were excluded mainly because they were not prospective follow up studies. Only a few studies were excluded because absolute numbers could not be extracted or results were not reported as calcification versus no calcification. The remaining 30 studies, which are summarized in [Table 1](#t1-vhrm-5-185){ref-type="table"}, could be included.[@b3-vhrm-5-185],[@b5-vhrm-5-185]--[@b9-vhrm-5-185],[@b13-vhrm-5-185],[@b15-vhrm-5-185]--[@b37-vhrm-5-185] Ten studies concerned plain radiography, such as mammograms, chest X-rays or X-rays of the peripheral blood vessels (eg, the femoral artery); ten studies had applied CT, mostly of the coronaries, and in 10 studies US had been used, predominantly of the heart valves. On plain radiographs vascular calcifications were defined as linear densities in the blood vessel area. With CT vascular calcification was defined as any vessel part with a density of 130 Hounsfield units or more. In the US studies highly echogenic plaques producing bright white echoes with shadowing were noted as calcifications. No reports with respect to MRI fulfilled the inclusion criteria. In these 30 papers, the absolute numbers of events in relation to the presence or absence of calcifications were reported, comprising a total of 218,080 subjects. Overall, 53% of the subjects were males. The prevalence of vascular calcifications varied according to the patient group studied. The lowest prevalence of 2.3% was found in an asymptomatic population with a mean age of 47 years in which aortic arch calcifications on plain chest X-rays were studied.[@b5-vhrm-5-185] The highest prevalence of 88.9% was found in patients (mean age 56 years) with chest pain in whom coronary calcifications were measured by electron beam computer tomography (EBCT).[@b24-vhrm-5-185] The median prevalence of calcification in all studies was 57.5%. The mean follow up to record the number of cardiovascular events in these studies was 10.1 years (range 2--26).

All cause mortality
-------------------

In nine studies, with a total of 3,821 deaths among the 40,747 participants, data on all cause mortality were re ported.[@b11-vhrm-5-185],[@b17-vhrm-5-185],[@b19-vhrm-5-185],[@b22-vhrm-5-185],[@b27-vhrm-5-185],[@b28-vhrm-5-185],[@b33-vhrm-5-185],[@b36-vhrm-5-185],[@b37-vhrm-5-185] Odds ratios are depicted in [Figure 1](#f1-vhrm-5-185){ref-type="fig"}. Among 16,528 subjects with calcifications 1,589 deaths were observed. Four of the studies comprised a population with renal insufficiency in which the event rate for all cause mortality in patients with calcifications was more than 5 times higher than in patients without calcifications. Overall OR for mortality from all causes was 4.62 (95% CI 2.24 to 9.53, [Figure 1](#f1-vhrm-5-185){ref-type="fig"}). The odds ratio for all cause mortality in patients without renal insufficiency was 3.43 (95% CI 1.26 to 9.32).

Cardiovascular mortality
------------------------

Odds ratios for cardiovascular mortality are also shown in [Figure 1](#f1-vhrm-5-185){ref-type="fig"}. A total of 1,356 cardiovascular deaths were observed among the 17,187 participants in the 9 studies that reported data on this complication.[@b8-vhrm-5-185],[@b9-vhrm-5-185],[@b13-vhrm-5-185],[@b22-vhrm-5-185],[@b27-vhrm-5-185],[@b28-vhrm-5-185],[@b30-vhrm-5-185],[@b33-vhrm-5-185],[@b36-vhrm-5-185] Among 3,657 subjects with calcifications, 718 cardiovascular deaths were observed. In two of the nine studies the imaging technique was US, one study employed CT, and in the remainder plain radiographs were used. The overall OR for cardiovascular mortality in the presence of calcifications was 3.94 (95% CI 2.39 to 6.50), but there was significant heterogeneity among the studies ([Figure 1](#f1-vhrm-5-185){ref-type="fig"}).

Coronary events
---------------

Data on coronary events were available in 16 studies (17,482 events among 173,650 subjects).[@b3-vhrm-5-185],[@b5-vhrm-5-185],[@b6-vhrm-5-185],[@b8-vhrm-5-185],[@b15-vhrm-5-185],[@b16-vhrm-5-185],[@b22-vhrm-5-185]--[@b24-vhrm-5-185],[@b28-vhrm-5-185],[@b29-vhrm-5-185],[@b31-vhrm-5-185],[@b33-vhrm-5-185]--[@b35-vhrm-5-185],[@b38-vhrm-5-185] In the 19,261 subjects with calcifications, 1,534 events were observed resulting in an overall OR of 3.74 (95% CI 2.56 to 5.45; [Figure 2](#f2-vhrm-5-185){ref-type="fig"}). Eight of these studies had utilized CT-scans of the coronaries and four used plain radiography. Thirteen studies originated from a North American population and most of the studies were done for screening purposes in an asymptomatic population. Average follow up in the CT-studies was only four years, but 18.7 years in the studies done with plain radiography.

Stroke
------

Stroke was reported as primary outcome in 11 studies with a total of 154,784 subjects of whom 9,889 showed calcifications.[@b5-vhrm-5-185]--[@b8-vhrm-5-185],[@b18-vhrm-5-185],[@b25-vhrm-5-185]--[@b28-vhrm-5-185],[@b33-vhrm-5-185],[@b39-vhrm-5-185] In the group with calcifications there were 874 stroke cases. The total number of events was 10,454. Only one out of five studies with ultrasound looked at calcifications of the carotid artery, whereas in the other four US of the heart valves was performed. The remaining six studies, all with plain radiographs, evaluated vascular calcifications of the breast, the thoracic or abdominal aorta and peripheral arteries. None of the studies with CT assessed the incidence of stroke. The overall OR for stroke was 2.21 (95% CI 1.81 to 2.69) in the presence of calcifications anywhere ([Figure 2](#f2-vhrm-5-185){ref-type="fig"}).

Any cardiovascular event
------------------------

In 27 studies with a total of 192,205 patients and 34,958 events, the risk for any cardiovascular event could be studied ([Figure 3](#f3-vhrm-5-185){ref-type="fig"}).[@b3-vhrm-5-185],[@b5-vhrm-5-185]--[@b9-vhrm-5-185],[@b12-vhrm-5-185],[@b15-vhrm-5-185],[@b16-vhrm-5-185],[@b18-vhrm-5-185],[@b22-vhrm-5-185]--[@b36-vhrm-5-185],[@b38-vhrm-5-185],[@b39-vhrm-5-185] In the 27,921 subjects with calcifications, 3,245 events were recorded. The average age was 59 years, but in the studies that reported the average age for the subjects with and without calcifications separately, age was significantly higher in those with calcifications (63 versus 56 years, p \< 0.05). The overall OR for any cardiovascular event with any modality was 3.41 (95% CI 2.71 to 4.30). This could be subdivided in an OR of 2.14 (95% CI 1.65 to 2.77) for ultrasound studies, 3.01 (95% CI 2.16 to 4.20) for plain radiographic studies, and 7.26 (95% CI 4.42 to 11.92) for studies using CT as diagnostic modality.

Meta regression analysis for any cardiovascular event
-----------------------------------------------------

Meta-regression analysis with respect to the outcome of any cardiovascular event showed that the type of imaging technique and the duration of follow up were significant causes of heterogeneity. After stratifying for imaging technique and follow up, the meta-analysis showed substantially lesser or no significant heterogeneity. [Figure 4](#f4-vhrm-5-185){ref-type="fig"} is shown as an example for the CT studies. However, the number of studies per group was also much smaller giving rise to less chance for heterogeneity.

When data of high risk populations or populations with renal insufficiency or diabetes mellitus were analyzed separately there was also no significant heterogeneity (chi-squared = 1.52 \[d.f. = 4\] p = 0.823, 3.59 \[d.f. =3\] p = 0.309 and 0.98 \[d.f. = 1\] p = 0.322, respectively) ([Figures 5](#f5-vhrm-5-185){ref-type="fig"}, [6](#f6-vhrm-5-185){ref-type="fig"}).

Subgroup analysis
-----------------

Most studies have been performed in asymptomatic populations participating in a screening program. In some, however, the indication for the test was the presence of one or more cardiovascular risk factors. The pooled OR for any cardiovascular event was 3.34 (95% CI 2.51 to 4.43) in studies with low baseline risk,[@b3-vhrm-5-185],[@b5-vhrm-5-185]--[@b8-vhrm-5-185],[@b15-vhrm-5-185],[@b16-vhrm-5-185],[@b18-vhrm-5-185],[@b22-vhrm-5-185],[@b23-vhrm-5-185],[@b25-vhrm-5-185],[@b26-vhrm-5-185],[@b31-vhrm-5-185],[@b32-vhrm-5-185],[@b35-vhrm-5-185] 3.65 (95% CI 1.87 to 7.12) for populations with intermediate risk[@b9-vhrm-5-185],[@b13-vhrm-5-185],[@b27-vhrm-5-185],[@b29-vhrm-5-185],[@b34-vhrm-5-185],[@b38-vhrm-5-185],[@b39-vhrm-5-185] and 4.20 (95% CI 2.44 to 7.23) in high risk subjects ([Figure 5](#f5-vhrm-5-185){ref-type="fig"}).[@b24-vhrm-5-185],[@b28-vhrm-5-185],[@b30-vhrm-5-185],[@b33-vhrm-5-185],[@b36-vhrm-5-185] There was no significant heterogeneity in the latter group for the pooled estimate.

When only subjects with renal insufficiency were considered the risk for any cardiovascular event in the presence of calcifications was even higher ([Figure 6](#f6-vhrm-5-185){ref-type="fig"}).[@b19-vhrm-5-185],[@b28-vhrm-5-185],[@b30-vhrm-5-185],[@b33-vhrm-5-185],[@b36-vhrm-5-185] All patients were on hemodialysis except for the patients in one study who were on continuous ambulatory peritoneal dialysis.[@b33-vhrm-5-185] In these five studies, comprising a total of 1098 persons, 124 events were observed. Among the 599 patients with calcifications, 104 had suffered an event. Odds ratios for any cardiovascular event were 6.22 (95% CI 2.73 to 14.14). This pooled estimate was without significant heterogeneity. Although the confidence intervals overlap, it seemed that the presence of calcifications had the highest predictive power for a cardiovascular or a cerebrovascular event in subjects with renal insufficiency.

Although three studies reported data from diabetic patients, only two of these gave sufficient information to calculate odds ratios for cardiovascular mortality (2.27, 95% CI 1.70 to 3.04).[@b9-vhrm-5-185],[@b27-vhrm-5-185] Of 1,192 patients, 508 had calcifications on plain radiography of the femoral arteries of which 139 of a total of 236 events occurred in the patients with calcifications.

Funnel plot
-----------

A funnel plot of the standard error of log odds ratio was performed to assess a possible publication bias ([Figure 7](#f7-vhrm-5-185){ref-type="fig"}). This is based on the fact that the precision in the estimation, of the underlying effect of finding calcification on outcome, will increase as the sample size of component studies increases. Effect estimates from small studies will therefore scatter more widely at the right of the graph, with the spread narrowing among larger studies to the left of the graph. In the absence of bias, the plot would appear to be symmetrical. Although it appears to be rather symmetrical, there are no studies in the right lower quadrant suggesting publication bias of small studies without any or a positive effect of calcification on cardiovascular events. However there was no bias using statistical tests for bias such as the Egger (weighted regression) method (p for bias 0.24) or the Begg (rank correlation) method.[@b14-vhrm-5-185]

Discussion
==========

The objective of this meta-analysis was to assess the risks associated with calcification of the arterial wall or cardiac valves, as observed with different imaging methods in populations with different baseline risk. We showed that the presence of calcification with any type of imaging technique in these populations harbors a 3--4 times increased risk for mortality and cardiovascular events.

The present meta-analysis has several limitations. Firstly, it was not possible to adjust for age in our analysis, since age was not provided in all studies. Although calcification becomes more prevalent with age, we had to use unadjusted data to assess the general risk of calcification as seen on any mode of investigation. However, in almost all individual studies calcification was an independent risk factor. Adjustment for age did not change their outcome substantially. Secondly, the possibility of publication bias has to be considered. The asymmetry as seen in the funnel plot suggests that this could be the case for small studies with no significant effect on any cardiovascular event with calcification. However, statistical tests did not indicate significant publication bias. Furthermore, there was significant heterogeneity among the studies that could largely be explained by the different investigational tools on the one hand and different duration of follow up on the other. For example, patients who are being evaluated by CT for coronary symptoms, run a substantially higher risk with a shorter time horizon than those in whom calcifications are found accidentally. When we analyzed the risk for any cardiovascular event separately in relation to the type of imaging technique and time of follow-up (\<5 years and \>5 years), heterogeneity disappeared for the US and CT studies ([Figure 4](#f4-vhrm-5-185){ref-type="fig"}), but significant heterogeneity remained present in studies using plain radiography with follow-up longer than five years. This persistent heterogeneity can possibly be explained by differences in population characteristics and calcification. In the studies with diabetic patients medial calcification was present in most cases. Medial calcification is associated with higher odds ratios for events than intimal calcifications in diabetic patients and might thus be an explanation for persistent heterogeneity in radiographic studies with a long follow-up period.[@b9-vhrm-5-185] Also the range of follow up time in these populations was much greater (2--26 years in plain radiograph studies, 1.5--16 in US studies, and 2.7--6.9 in CT studies).

With respect to selection mechanisms and baseline risk, subgroup analysis of a renal insufficiency population showed the highest risk. CT data predicted the events best with the highest odds ratio. Moreover, when calcium was seen with coronary CT, events occurred after a relatively short follow up period. Although coronary calcifications as detected by CT were associated with a greater risk of events than calcification in other areas, the difference in study populations preclude meaningful conclusions about the superiority of CT relative to other imaging modalities. Moreover, compared with plain X-rays or ultrasound studies, noncontrasted CT scans and EBCT are likely to be more sensitive for detecting small amounts of calcification. Interestingly, in hemodialysis patients were plain radiography or US were used to detect calcifications some of the highest odds ratios for all cause mortality and cardiovascular mortality were seen.[@b19-vhrm-5-185],[@b28-vhrm-5-185],[@b30-vhrm-5-185],[@b33-vhrm-5-185],[@b36-vhrm-5-185] This might reflect their lower sensitivity for detecting any calcification. Half of the studies that reported on all cause mortality concerned a high-risk patient group with renal insufficiency. This influenced the odds ratio resulting in a relatively high risk for all cause mortality. Nevertheless, when we calculated the odds ratio for populations without renal insufficiency, this was still significantly increased (3.43; 95% CI 1.26 to 9.32).

The results of this meta-analysis help to clarify the importance of calcification in all sorts of patients. Although the reported odds ratios should be interpreted with caution because of substantial heterogeneity across studies, it showed that in almost any case of calcification there is an increased cardiovascular risk. It is important to realize that subjects with vascular calcification are high-risk patients. Currently, however, there is no specific therapy to reduce these calcifications and no evidence to support a better cardiovascular outcome with calcification reduction, although data from animal research and from human cells *in vivo* on the actions of matrix Gla protein as an active calcification inhibitor show promising results.[@b40-vhrm-5-185]--[@b42-vhrm-5-185] The use of statins reduces the cardiovascular event rate in almost all patient groups, but data on their calcification inhibiting properties are conflicting.[@b43-vhrm-5-185]--[@b48-vhrm-5-185]

To our knowledge, there are no studies exploring the effect of treating all cardiovascular risk factors in patients based only on the presence of calcifications. However, extensive coronary calcifications justify further investigations for coronary plaques. Therefore, we feel that the practicing physician is also justified to screen subjects, in whom calcifications are accidentally detected, for treatable risk factors. If these are present, the cardiovascular risk according to risk charts should be assessed. If the outcome exceeds the threshold defined in guidelines, the physician should take measures to reduce the cardiovascular risk of his or her patient.

None of the authors had any conflict of interest to the subject of this manuscript. RJMW Rennenberg and AA Kroon had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. There were no commercial funding sources involved.

![Odds ratios for mortality, all cause and cardiovascular, when calcification is present.\
**Notes:** Heterogeneity for all cause mortality chi-squared = 248.98 (d.f. = 8) p = 0.000; Heterogeneity for cardiovascular mortality chi-squared = 61.52 (d.f. = 8) p = 0.000.](vhrm-5-185f1){#f1-vhrm-5-185}

![Odds ratios for coronary events and stroke, when calcification is present.\
**Notes:** Heterogeneity for coronary events chi-squared = 154.86 (d.f. = 15) p = 0.000; Heterogeneity for stroke chi-squared = 21.67 (d.f. = 10) p = 0.017.](vhrm-5-185f2){#f2-vhrm-5-185}

![Risk for any cardiovascular event when calcification is present.\
**Notes:** Heterogeneity chi-squared = 198.94 (d.f. = 26) p = 0.000.](vhrm-5-185f3){#f3-vhrm-5-185}

![Results for any cardiovascular event stratified for imaging modality and follow up.\
**Notes:** Heterogeneity chi-squared in only CT studies = 22.32 (d.f. = 8) p = 0.004; Heterogeneity chi-squared in CT studies with follow up shorter than 5 years = 3.57 (d.f. = 6) p = 0.735; Heterogeneity chi-squared in CT studies with follow up longer than 5 years = 0.01 (d.f. = 1) p = 0.934.](vhrm-5-185f4){#f4-vhrm-5-185}

![Risk for any cardiovascular event due to calcification according to baseline risk.\
**Notes:** Heterogeneity in the low risk group chi-squared = 139.74 (d.f. = 14) p = 0.000; Heterogeneity in the intermediate risk group chi-squared = 55.79 (d.f. = 6) p = 0.000; Heterogeneity in the high risk group chi-squared = 1.52 (d.f. = 4) p = 0.823.](vhrm-5-185f5){#f5-vhrm-5-185}

![Subgroup analysis for renal insufficiency and diabetes mellitus.\
**Notes:** Heterogeneity in the renal insufficiency group chi-squared = 3.59 (d.f. = 3) p = 0.309; Heterogeneity in the diabetes mellitus group chi-squared = 0.98 (d.f. = 1) p = 0.322.](vhrm-5-185f6){#f6-vhrm-5-185}

![Funnel plot of standard error of log(OR) for any cardiovascular event.\
**Notes:** Begg's funnel plot of published studies reporting any cardiovascular event. The fact that many studies are outside the 95% confidence interval, indicated by the sloping lines, is caused by heterogeneity of the studies.](vhrm-5-185f7){#f7-vhrm-5-185}

###### 

General characteristics of the included studies

  **Population**                                                     **Author**                   **Year of publication**   **Number of subjects**   **Mean follow up**                               **Male (%)**   **Mean age (Year)**   **Modality**       **Location**                                         **Total events (n)**   **Prevalence of calcification**
  ------------------------------------------------------------------ ---------------------------- ------------------------- ------------------------ ------------------------------------------------ -------------- --------------------- ------------------ ---------------------------------------------------- ---------------------- ---------------------------------
  Asymptomatic                                                       Arad[@b16-vhrm-5-185]        2005                      4613                     4.3                                              65             59                    EBCT               Coronary arteries                                    129                    67.4
  Asymptomatic                                                       Kondos[@b3-vhrm-5-185]       2003                      5635                     3.1                                              74             51                    EBCT               Coronary arteries                                    223                    68.0
  Asymptomatic                                                       Taylor[@b31-vhrm-5-185]      2005                      1983                     3                                                82             43                    EBCT               Coronary arteries                                    9                      18.4
  Asymptomatic                                                       Wong[@b34-vhrm-5-185]        2000                      926                      3.3                                              79             54                    EBCT               Coronary arteries                                    28                     57.0
  Asymptomatic                                                       LaMonte[@b15-vhrm-5-185]     2005                      10746                    3.5                                              64             54                    EBCT               Coronary arteries                                    287                    49.1
  Asymptomatic                                                       Becker[@b13-vhrm-5-185]      2008                      1726                     3.4                                              59             58                    EBCT               Coronary arteries                                    380                    78
  Asymptomatic                                                       Budoff[@b17-vhrm-5-185]      2007                      25253                    6.8                                              54             56                    EBCT               Coronary arteries                                    900                    56.3
  Asymptomatic                                                       Hollander[@b7-vhrm-5-185]    2003                      5631                     5.2                                              40             70                    Plain radiograph   Abdominal aorta                                      269                    66.6
  Asymptomatic                                                       Iribarren[@b5-vhrm-5-185]    2000                      116309                   28[†](#tfn2-vhrm-5-185){ref-type="table-fn"}     48             47                    Plain radiograph   Aortic arch                                          28501                  2.3
  Asymptomatic                                                       Iribarren[@b6-vhrm-5-185]    2004                      12761                    24.8[†](#tfn2-vhrm-5-185){ref-type="table-fn"}   0              56                    Plain radiograph   Breasts                                              1672                   3.3
  Asymptomatic                                                       Kemmeren[@b8-vhrm-5-185]     1998                      12084                    16--19                                           0              58                    Plain radiograph   Breasts                                              574                    9.2
  Asymptomatic                                                       Walsh[@b32-vhrm-5-185]       2002                      2214                     22                                               40             61                    Plain radiograph   Abdominal aorta                                      241                    59.8
  Asymptomatic                                                       Benjamin[@b18-vhrm-5-185]    1992                      1159                     8                                                37             70                    Ultrasound         Mitral valve                                         73                     13.8
  Asymptomatic                                                       Fox[@b22-vhrm-5-185]         2003                      1197                     16                                               37             70                    Ultrasound         Mitral valve                                         307                    14.1
  Asymptomatic                                                       Kitamura[@b25-vhrm-5-185]    2004                      1287                     4.5                                              n.a.           66                    Ultrasound         Carotid arteries                                     34                     9.9
  Asymptomatic                                                       Kizer[@b26-vhrm-5-185]       2005                      2723                     7[†](#tfn2-vhrm-5-185){ref-type="table-fn"}      35             59                    Ultrasound         Mitral valve                                         86                     9.3
  Asymptomatic                                                       Gardin[@b35-vhrm-5-185]      2001                      3673                     5.9                                              42             73                    Ultrasound         Mitral valve                                         455                    6.6
  Chest pain                                                         Keelan[@b24-vhrm-5-185]      2001                      288                      6.9                                              77             56                    Ebct               Coronary arteries                                    22                     88.9
  Diabetics                                                          Lehto[@b27-vhrm-5-185]       1996                      1059                     7                                                55             58                    Plain radiograph   Femoral arteries                                     208                    41.5
  Diabetics                                                          Niskanen[@b9-vhrm-5-185]     1994                      133                      10                                               53             56                    Plain radiograph   Femoral arteries                                     28                     51.9
  Multiple risk factors[\*](#tfn1-vhrm-5-185){ref-type="table-fn"}   Raggi[@b29-vhrm-5-185]       2000                      632                      2.7                                              50             52                    Ebct               Coronary arteries                                    27                     53.8
  Multiple risk factors[\*](#tfn1-vhrm-5-185){ref-type="table-fn"}   Greenland[@b38-vhrm-5-185]   2004                      1029                     6.3                                              90             65                    Msct               Coronary arteries                                    84                     69.3
  Multiple risk factors[\*](#tfn1-vhrm-5-185){ref-type="table-fn"}   Boon[@b39-vhrm-5-185]        1996                      1377                     2.3                                              50             63                    Ultrasound         Aortic and mitral valve                              75                     59.2
  Multiple risk factors[\*](#tfn1-vhrm-5-185){ref-type="table-fn"}   Fox[@b23-vhrm-5-185]         2004                      2409                     4.8                                              36             59                    Ultrasound         Mitral valve                                         132                    4.9
  Multiple risk factors[\*](#tfn1-vhrm-5-185){ref-type="table-fn"}   Willens[@b37-vhrm-5-185]     2006                      135                      5                                                100            64                    Ultrasound         Mitral valve                                         38                     37
  Renal insufficiency                                                Blacher[@b19-vhrm-5-185]     2001                      110                      4.4                                              62             54                    Plain radiograph   Carotid, abdominal aorta, ileofemoral arteries       39                     66.4
  Renal insufficiency                                                London[@b28-vhrm-5-185]      2003                      202                      7.4                                              42             54                    Plain radiograph   Ileofemoral axis                                     46                     63.9
  Renal insufficiency                                                Salgueira[@b30-vhrm-5-185]   2003                      79                       \>2                                              54             48                    Plain radiograph   Aortic arch, abdominal aorta, ileofemoral arteries   8                      55.7
  Renal insufficiency                                                Okuno[@b36-vhrm-5-185]       2007                      515                      4.3                                              59             60                    Plain radiograph   Abdominal aorta                                      103                    56.5
  Renal insufficiency                                                Wang[@b33-vhrm-5-185]        2003                      192                      1.5                                              51             55                    Ultrasound         Aortic and mitral valve                              24                     32.3

**Notes:** \*Multiple risk factors but asymptomatic subjects,

^†^Indicates median follow up.

**Abbreviations:** n.a., not available; EBCT, electron beam computer tomography; MSCT, multi slice computer tomography.
